One of the main obstacles of conventional anticancer therapy is the toxicity of chemotherapeutics to normal tissues. So far, clinical approaches that aim to specifically reduce chemotherapy-mediated toxicities are rare. Recently, a number of studies have demonstrated that herbal extracts derived from traditional Chinese medicine (TCM) may reduce chemotherapy-induced side effects. Thus, we screened a panel of published cancer-inhibiting TCM compounds for their chemoprotective potential and identified the phytochemical Rocaglamide (Roc-A) as a candidate. We show that Roc-A significantly reduces apoptotic cell death induced by DNA-damaging anticancer drugs in primary human and murine cells. Investigation of the molecular mechanism of Roc-A-mediated protection revealed that Roc-A specifically blocks DNA damage-induced upregulation of the transcription factor p53 by inhibiting its protein synthesis. The essential role of p53 in Roc-A-mediated protection was confirmed by siRNA knockdown of p53 and by comparison of the effects of Roc-A on chemoprotection of splenocytes isolated from wild-type and p53-deficient mice. Importantly, Roc-A did not protect p53-deficient or -mutated cancer cells. Our data suggest that Roc-A may be used as an adjuvant to reduce the side effects of chemotherapy in patients with p53-deficient or -mutated tumors.
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Natural products are an important source of drugs in medicine. Recently, several studies showed that herbal extracts from traditional Chinese medicine (TCM) could reduce chemotherapy-induced side effects in vivo. [7] [8] [9] [10] For instance, the herbal mixture PHY906, which is based on the TCM Huang Qin Tang, reduced CPT-11-induced toxicity in mice, 10 a finding that is further supported by a phase 1/2 clinical trial. 11 Other clinical studies suggest that Chinese herbal extracts may reduce the chemotherapy-induced decrease in white blood cell counts. 12 These results prompted us to investigate TCM compounds that could protect normal tissues from DNA damage-induced cell death.
In this study, we screened a panel of known cancerinhibiting TCM compounds for their chemoprotective potential and found that Rocaglamide (Roc-A) reduces DNA damageinduced apoptosis in nonmalignant primary cells. Roc-A belongs to a group of phytochemicals, characterized by a cyclopenta[b]-tetrahydrobenzofuran backbone, collectively named rocaglamides that are isolated from the TCM plant Aglaia. [13] [14] [15] Roc-A and its derivatives have been shown to possess anticancer activities in vitro in various tumor cell lines and patient samples and to inhibit tumor growth in vivo in several mouse tumor models. 14, 15 The primary effect of rocaglamides on tumor growth inhibition was shown to be caused by inhibition of protein synthesis. 16, 17 Two mechanisms, which ultimately lead to inactivation of the mRNA cap-binding eukaryotic translation initiation factor eIF4E and the translation initiation factor eIF4A, result in inhibition of protein synthesis. 18, 19 We further investigated the molecular mechanisms by which Roc-A protects normal cells from DNA damage-induced cell death and revealed that the transcription factor p53 is essential for this protection. It is well known that p53 plays an important role in the DNA damage response by inducing the expression of DNA repair proteins and also of genes involved in apoptosis, for example, BBC3 (PUMA) and BAX. When DNA damage exceeds a certain threshold and DNA repair fails, damaged cells undergo apoptosis. 1, 20 We show that Roc-A prevents DNA damage-induced apoptosis in normal cells by inhibition of p53 expression at the translational level. Importantly, p53-deficient and mutant tumor cells are not protected by Roc-A from DNA damage-induced cell death.
Results
Roc-A protects nonmalignant cells against DNA damage-induced cytotoxicity. To identify TCM compounds that can protect nontransformed primary cells from DNA damage-induced cytotoxicity, we performed a cell viability screen. Human peripheral blood T lymphocytes (T cells) from healthy donors were used as a model cell for healthy tissue. T cells were treated with the genotoxic chemotherapeutic drug Etoposide in the absence or presence of different TCM compounds. After 24 h of treatment, cell viability was determined by the Cell-Titer Glo viability assay (Promega, Mannheim, Germany). Among the analyzed compounds, Roc-A showed the strongest chemoprotective effect on T cells by reducing Etoposide-induced cytotoxicity by more than twofold ( Figure 1a ). Therefore, we focused on Roc-A for further analysis.
To validate the screening results, we treated normal T cells with increasing concentrations of Etoposide with or without different concentrations of Roc-A. After 24 h of treatment, apoptotic cell death was measured by specific DNA fragmentation, AnnexinV staining or determination of apoptotic-like changes in cell size and cellular granularity (FSC/SSC profile). The experiments showed that Etoposide treatment caused cell death of normal T cells that was reduced in the presence of Roc-A in a dose-dependent manner to 450% (Figure 1b To investigate whether Roc-A could also protect normal cells from cell death induced by other DNA damaging anticancer drugs, we treated T cells with increasing doses of Teniposide, Doxorubicin and Bleomycin in the presence or absence of Roc-A. The experiment showed that Roc-A could reduce drug-induced apoptosis in all cases ( Figure 1c ).
Next, we asked whether Roc-A could also protect other normal primary cells from DNA damage-induced toxicity. To address this question, we examined the protective effect of Roc-A on Etoposide-treated human peripheral blood B cells, NK cells, neutrophils, cardiomyocytes and murine hematopoietic stem and progenitor cells (HSPCs). The experiments revealed that all examined cells were protected by Roc-A against Etoposide-induced apoptosis (Figure 1d ). Taken together, these data indicate that Roc-A can protect primary nonmalignant cells from DNA damage-induced cytotoxicity.
Roc-A exerts its protection downstream of DNA damage. Genotoxins such as Etoposide induce apoptosis mainly through induction of DNA damage. 21 We therefore asked whether Roc-A could prevent genotoxin-induced DNA damage and thereby reduces genotoxin-induced cell death. To address this question, we determined the level of the DNA-damage marker g-H2AX that is generated around the site of a DNA DSB. 22 Etoposide treatment resulted in an increase in g-H2AX foci formation in a concentration-and time-dependent manner (Figures 2a and b) . A maximum amount of g-H2AX foci formation was observed at 4 h after treatment ( Figure 2b ). However, Roc-A did not block Etoposide-induced g-H2AX foci formation (Figures 2a-c). Similar results were obtained by alkaline single-cell gel electrophoresis assay (Comet assay) that detects both DNA single-strand breaks (SSBs) and DSBs (Figure 2d and e). Therefore, the protective effect of Roc-A appears to be downstream of DNA damage.
Roc-A inhibits DNA damage-induced increase in p53 expression. The transcription factor p53 is a major regulator of DNA damage-induced apoptosis. 23 Therefore, we investigated the effect of Roc-A on the expression level of p53. T cells were treated with increasing concentrations of Etoposide in the presence or absence of Roc-A and p53 protein expression was analyzed by immunoblot. The experiment showed that Etoposide treatment increased p53 protein levels. However, in the presence of Roc-A, p53 expression was blocked in a dose-dependent manner (Figure 3a ). Roc-A-mediated suppression of p53 upregulation was not specific for Etoposide, as inhibition was also observed in Bleomycin-, Teniposide-and Doxorubicin-treated cells ( Figure 3b ). Kinetic analysis showed that the increase in p53 protein levels could be detected as early as 4 h after Etoposide treatment and reached the highest level at 24 h (Figure 3c and Supplementary Figure S2 ). Roc-A could inhibit upregulation of p53 at all time points analyzed ( Figure 3c ). The time of p53 upregulation coincided with the onset of apoptosis induction (Figure 1b ). To ensure that Roc-A-mediated suppression of p53 upregulation was not only specific for T cells, the effect of Roc-A on p53 expression was also examined in B and NK cells treated with Etoposide. Consistent with the results obtained for T cells, Etoposide-induced p53 increase in B and NK cells was also suppressed by Roc-A (Figures 3d and e ). These data indicate that Roc-A might protect normal tissue from DNA damage-induced apoptosis by downregulation of genotoxin-induced p53 expression.
p53 plays an essential role in Roc-A-mediated protection.
To investigate the role of p53 in Roc-A-mediated protection of normal tissue, we induced p53 upregulation without the induction of DNA damage. To do so, T cells were treated with Nutlin-3 which has been shown to increase p53 protein levels by preventing Mdm2-mediated p53 degradation. 24 This experiment showed that Roc-A could also inhibit Nutlin-3induced p53 upregulation and, consequently, cell death ( Figure 4a ). Thus, Roc-A does not solely affect DNA damage-induced cell death, but may in general affect p53mediated cell death. This assumption was supported by analysis of p53 target genes that are involved in apoptosis regulation. For instance, Etoposide-induced increase in BAX, MDM2, BBC3 (PUMA) and FAS mRNA expression was blocked in the presence of Roc-A ( Figure 4b ). As a control, the mRNA level of BCL2L11 (BIM), whose expression is not regulated by p53, 25 was shown not to be considerably affected by Roc-A ( Figure 4b ).
To further investigate the role of p53 in Roc-A-mediated protection of T cells against DNA damage-induced apoptosis, we performed a p53-knockdown experiment using two siRNAs directed against p53 which yielded similar results ( (Figure 4c , lower panel). As siRNA-mediated knockdown of p53 could not fully block p53 expression, we examined the effect of Roc-A on p53 knockout (KO) cells. Splenocytes derived from wildtype (WT) and p53-KO mice were treated with Etoposide in the presence or absence of Roc-A. In line with the data observed in primary human cells, Roc-A protected splenocytes derived from p53-WT but not from p53-KO animals against Etoposide-induced cell death (Figure 4d ). These results demonstrate that p53 plays an essential role in Roc-Amediated chemoprotection.
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Roc-A does not protect malignant cells with nonfunctional p53. As Roc-A-mediated protection of nonmalignant cells from DNA damage-induced cell death is largely p53 dependent, we predicted that Roc-A may protect cancer cells having functional p53 but would not protect cancer cells having nonfunctional p53. As expected, Roc-A neither protected p53-mutated (L1236, 26 Hut-78, 27 DND-41 28 and SCLC-21H 29 ) nor p53-deficient (HL-60 29 ) cancer cell lines against Etoposide-induced cell death ( Figure 5a ). We then further tested cancer cell lines EU-3, 30 IM-9, 31 Reh, 30 SKW6.4 32 and NCI-H209 33 that have a WT p53 protein. The experiments showed that EU-3, SKW6.4 and IM-9 cells were protected by Roc-A from Etoposide-induced cell death but to a lesser extent than nonmalignant cells (Figure 5b and Supplementary Figure S3 ). Thus, Roc-A may also protect some p53-WT tumors from DNA-damaging drugs.
Roc-A suppresses p53 upregulation via inhibition of protein synthesis. The protein expression of p53 can be regulated at the level of transcription, translation and ubiquitination-mediated degradation. 34 It has been shown that upon DNA damage p53 undergoes post-translational modifications leading to its deubiquitination and, thus, stabilization. 35 To investigate whether Roc-A could decrease p53 stability, we treated T cells with the proteasome inhibitor Bortezomib to block proteasome-mediated degradation. Bortezomib treatment led to an increase in p53 in the absence of Roc-A ( Figure 6a ). However, Bortezomib could not increase p53 in the presence of Roc-A and also did not interfere with the ability of Roc-A to block Etoposide-induced p53 upregulation (Figure 6a ). To further investigate the effect of Roc-A on p53 stability, the status of p53 ubiquitination was analyzed after Etoposide treatment in the absence or presence of Roc-A. Etoposide treatment led to a decrease in p53 ubiquitination. However, Roc-A had no effect on p53 ubiquitination (Figure 6b ). These results demonstrate that Roc-A is unlikely to suppress p53 upregulation through decreasing p53 stability.
In addition, p53 has been shown to be upregulated at the translational level following DNA damage. 36, 37 Roc-A has been well documented to inhibit protein translation. 18, 19, 38, 39 Thus, we hypothesized that Roc-A-mediated suppression of genotoxin-induced p53 upregulation may be caused by inhibition of p53 protein synthesis. To test this, we examined the effects of different Roc-A derivatives that have been shown to exert different activities on inhibition of ERKmediated protein synthesis. 18 By means of [ 35 S]methionine incorporation analysis, Roc-A, -AB, -J, -AR and -Q, which have been shown to inhibit ERK activation with different efficacies, 18 inhibited [ 35 S]methionine incorporation at different degrees that correlated with different levels of protection of normal T cells from Etoposide-induced cell death (Figure 6c ). In contrast, Roc-AA, -AF and -I, which do not show any or very little inhibitory effect on ERK activity, 18 did not inhibit protein translation and did not protect T cells against Etoposideinduced cytotoxicity (Figure 6c ).
To confirm that Roc-A inhibits p53 protein synthesis, we carried out a [ 35 S]methionine-metabolic pulse-labeling experiment and then immunoprecipitated p53 after Etoposide treatment. The experiment showed that Roc-A suppressed [ 35 S]methionine incorporation into the p53 protein (Figure 6d ). To further exclude that Roc-A influences p53 expression at the transcriptional level, we examined p53 mRNA expression levels upon Etoposide treatment in the presence of Roc-A or solvent (DMSO) by quantitative real-time PCR. The experiment showed that Roc-A does not reduce p53 mRNA expression in Etoposide-treated cells (Figure 6e ). Thus, Roc-A suppresses DNA damage-induced upregulation of p53 at the translational level.
Discussion
Chemotherapy is broadly used among current standard treatment modalities for cancer patients, in particular for patients suffering from metastases. Most currently used anticancer drugs are genotoxins that induce DNA damage. This therapy has a major drawback of causing severe side effects. Because of these side effects, dosages have to be reduced or the treatment has to be discontinued completely.
In this study we show that the TCM compound Roc-A can reduce DNA-damaging drug-induced cytotoxicity in human and murine primary cells. The protective effect of Roc-A is not limited to a certain cell type or a specific DNA-damaging agent (Figure 1) . Thus, our data strongly suggest a potential use of Roc-A as a chemoprotective agent. Investigation of the molecular mechanisms by which Roc-A protects normal cells from chemotherapy-induced cytotoxicity revealed that p53 is a key factor in Roc-A-mediated protection. We show that Roc-A does not reduce genotoxininduced DNA damage (Figure 2 ), but inhibits genotoxininduced upregulation of p53 in different primary cells (Figure 3) . The essential role of p53 in Roc-A-mediated protection is evidenced by the following: (Figure 4d ). These data are consistent with the fact that p53 is involved in DNA damage-induced apoptosis 23, 40 and that decreased p53 protein levels confer resistance to a large number of DNAdamaging chemotherapeutics in vitro 23, 40 and in vivo. 41 Approximately 50% of all known cancers are either deficient for p53 or carry a mutation in p53 that abolishes p53-WT function. 42 We show that Roc-A does not protect Etoposidetreated tumor cell lines that either contain p53 mutations (L1236, 26 Hut-78, 27 DND-41 28 and SCLC-21H 29 ) or that are p53-deficient (HL-60 29 ) (Figure 5a ). These results indicate that Roc-A may be used to reduce the side effects of chemotherapy in the treatment of p53-deficient or -mutated cancers. As p53 plays a decisive role in Roc-A-mediated protection, one can presume that Roc-A may protect p53-WT tumors against genotoxin-induced cell death. As predicted, Roc-A was shown to indeed reduce Etoposide-induced cell death in several p53-WT tumor cell lines including EU-3 acute lymphoblastic leukemia cells, SKW6.4 leukemic B cells and IM-9 chronic myeloid leukemia cells (Figure 5b ). However, the protective effect of Roc-A on p53-WT tumor cells was less efficient compared with nonmalignant cells (Figure 1 and Supplementary Figure S3 ). Intriguingly, some p53-WT tumor cells, for example, the acute lymphoblastic leukemia cell line Reh and the small cell lung cancer cell line NCI-H209, were not protected by Roc-A (Figure 5b ). This result may be explained by mutations of genes in the p53 signaling pathway that often occur in p53-WT cancers. 42, 43 In addition, Roc-A has been shown to have a much higher cytotoxicity on cancer than on nonmalignant cells by differential regulation of activities of mitogen-activated protein kinases. 44 Furthermore, Roc-A has been shown to inhibit the Ras/CRaf/MEK/ERK signaling pathway that is one of the key signaling pathways regulating tumor survival. 18, 45 In this study, we also investigated the molecular mechanism by which Roc-A inhibits DNA damage-induced p53 upregulation. Under unstressed conditions, p53 is negatively regulated by Mdm2 that binds to and inhibits p53 activity and leads to its degradation by the ubiquitination-mediated proteasomal pathway. 46 Genotoxic stress has been shown to inhibit Mdm2-mediated p53 degradation and increase the stability and, consequently, protein levels of p53. 35 Our experiments showed that Roc-A neither alters the basal level of p53 ubiquitination nor the level of p53 ubiquitination upon Etoposide treatment (Figure 6b ). Moreover, blocking proteasomal activity did not lead to a reduction in Roc-A-mediated suppression of p53 upregulation (Figure 6a ). Thus, we conclude that Roc-A does not affect p53 stability. Genotoxic stress can also increase the expression of p53 at the translational level. 36, 37 Roc-A and its derivatives are potent inhibitors of protein synthesis. 14, 15, 18, 19, 38 Indeed, Roc-A and its active derivatives Roc-AB, J, AR and Q, 18 but not the inactive derivatives Roc-AA, AF and I, 18 were shown to inhibit Etoposide-induced protein translation (Figure 6c ). The degree of translation inhibition correlated with the efficacy of chemoprotection by Roc-A and its derivatives (Figure 6c ). Moreover, Roc-A was shown to inhibit p53 translation (Figure 6d ). Furthermore, Roc-A did not reduce the mRNA levels of p53 (Figure 6e ). These data demonstrate that Roc-A inhibits DNA damage-induced upregulation of p53 by inhibition of protein synthesis. p53 is a well-known tumor suppressor. Thus, blocking p53 expression might increase the risk of tumor development. However, a number of studies show that transient pharmacological or genetic inactivation of p53 before or after genotoxic stress does not lead to increased carcinogenesis. [47] [48] [49] Moreover, recent publications indicate that the tumor-suppressor function of p53 is independent from its functions on apoptosis and cell cycle. 50, 51 In this study, we also show that, in principle, all bioactive derivatives of Roc-A may protect normal cells from genotoxininduced cytotoxicity (Figure 6c ). In line with our studies, several compounds belonging to the same structural family of Roc-A were recently shown to protect rat and murine cardiomyocytes against doxorubicin-induced apoptosis. 52, 53 Doxorubicin is also a DNA-damaging anticancer drug. Therefore, cardioprotection by these compounds may also involve p53. Moreover, p53 has been implicated in certain neurological disorders, such as Alzheimer's and Parkinson's disease. 54, 55 Interestingly, some structural-related compounds of Roc-A were shown to have neuroprotective effects in vitro on neuron cells and in vivo in animal models of Parkinson's disease and stroke. 53, 56 In this regard, our results may offer a potential mechanism for the neuroprotective action of these compounds.
Taken together, our data demonstrate that Roc-A selectively protects nonmalignant human primary cells against DNA damage-induced apoptosis via a p53-dependent mechanism. Thus, Roc-A and its derivatives may be attractive compounds for the treatment of side effects of current chemotherapy. Following storage at À 201C overnight, cells were incubated with mouse serum to block unspecific binding and stained with antibody directed against g-H2AX (AlexaFluor 488-coupled, 2F3; BioLegend, Fell, Germany), or with isotype control antibody (AlexaFluor 488-coupled; BioLegend). The amount of g-H2AX foci formation was determined by FACS measurement. Cell aliquots were taken and confocal microscopy was carried out to visualize Etoposide-induced g-H2AX foci formation. Nuclei were stained with DAPI mounting medium (Dianova, Hamburg, Germany). Comet assays were carried out as previously described. 59 Briefly, electrophoresis of cellular genomic DNA was performed under alkaline conditions at 41C. The amount of DNA damage was measured by 'Olive Tail Moment'. Analysis of cellular DNA damage was carried out by fluorescence microscopy, using a fully automated cell scanning system Metafer-4 (Metasystems, Altluheim, Germany).
Materials and Methods
RNA isolation and quantitative real-time PCR. Total cellular RNA was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. Reverse Transcription of RNA into cDNA was carried out by use of the High Capacity cDNA reverse transcription kit (Applied Biosystems). Quantitative real-time PCR was performed with an ABI Prism 7500 standard qRT-PCR cycler (Applied Biosystems) following the incorporation of SYBR Green. Reactions were carried out in triplicate. Relative gene expression levels were determined by normalization to the expression level of the housekeeping gene HPRT1. The DDCt method 60 was used to calculate fold expression levels.
The following primers were used: HPRT1 (forward: 5 0 -TGACACTGGCAAAACAAT GCA-3 0 , reverse: 5 0 -GGTCCTTTTCACCAGCAAGCT-3 0 ), BBC3 (PUMA) (forward: 5 0 -GAAGAGCAAATGAGCCAAACG-3 0 , reverse: 5 0 -GGAGCAACCGGCAAACG-3 0 ), MDM2 (forward: 5 0 -ACCTCACAGATTCCAGCTTCG-3 0 , reverse: 5 0 -TTTCATAG TATAAGTGTCTTTTT-3 0 ), FAS (forward: 5 0 -AGCTTGGTCTAGAGTGAAAA-3 0 , reverse: 5 0 -GAGGCAGAATCATGAGATAT-3 0 ), BAX (forward: 5 0 -GCTGTTG GGCTGGATCCAAG-3 0 , reverse: 5 0 -TCAGCCCATCTTCTTCCAGA-3 0 ), BCL2L11 (BIM) (forward: 5 0 -ATCCCCGCTTTTCATCTTTA-3 0 , reverse: 5 0 -AGGACTTG GGGTTTGTGTTG-3 0 ), TP53 (forward: 5 0 -TCAACAAGATGTTTTGCCAACTG -3 0 , reverse: 5 0 -ATGTGCTGTGACTGCTTGTAGATG -3 0 ).
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